MARC details
| 000 -LEADER |
|---|
| fixed length control field |
04018nmi a22003737a 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20250220145342.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS |
|---|
| fixed length control field |
m||||| |||| 00| 0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
c| zz uauuu |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
180124d2024 sp ||||| |||| 00| 0 spa d |
| 040 ## - CATALOGING SOURCE |
|---|
| Transcribing agency |
Salus Infirmorum |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Clavel Fernández, Ignacio |
| 9 (RLIN) |
4403 |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Efectividad del Dinutuximab en el tratamiento del neuroblastoma en niños / |
| Statement of responsibility, etc. |
Ignacio Clavel Fernández Tutora: Elena Jiménez |
| Medium |
[Trabajo Fin de Grado] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Date of publication, distribution, etc. |
2024 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
1 archivo (pdf.) ; |
| Dimensions |
566 KB |
| 500 ## - GENERAL NOTE |
|---|
| General note |
Trabajo fin de grado. Defendido en 2024 |
| 520 3# - SUMMARY, ETC. |
|---|
| Summary, etc. |
Introducción:<br/>El neuroblastoma es un tumor que tiene una gran incidencia en niños. Existen diversas líneas de tratamiento para este tumor, en pacientes con la enfermedad de alto riesgo.<br/>En este trabajo se abordará los tratamientos del neuroblastoma en pacientes de alto riesgo en combinación con anticuerpos monoclonales.<br/>Objetivo:<br/>Determinar la efectividad del anticuerpo monoclonal dinutuximab, en cuanto a efectos adversos, tasas de supervivencia y respuestas, en pacientes pediátricos con neuroblastoma de alto riesgo.<br/>Material y métodos:<br/>Para la realización de este estudio se ha realizado una revisión bibliográfica de artículos científicos a través de diferentes bases de datos electrónicas, en concreto Pubmed, Cochrane y Scopus.<br/>Resultados:<br/>En relación con los criterios de inclusión, se obtuvieron un total de 8 artículos para el estudio centrados en la efectividad del tratamiento del neuroblastoma en pacientes de alto riesgo con anticuerpos monoclonales. Se utilizó el anticuerpo monoclonal dinutuximab para analizar las tasas de supervivencias, y por otro lado se han analizado los efectos adversos identificados en el tratamiento, comparándolas con tratamiento sin dinutuximab.<br/>Conclusiones:<br/>En síntesis, se ha demostrado que el tratamiento con dinutuximab en pacientes con neuroblastoma de alto riesgo, ha demostrado un aumento tanto en las tasas de supervivencia, como un buen número de respuestas al tratamiento, además de haber analizado los efectos adversos referidos en las infusiones. |
| 520 8# - SUMMARY, ETC. |
|---|
| Summary, etc. |
Introduction:<br/>Neuroblastoma is a tumor that predominantly affects children and has a high incidence rate. There are various treatment approaches available for this disease in high-risk patients. This study focuses on treatments for neuroblastoma in high-risk patients involving the use of monoclonal antibodies.<br/>Objective:<br/>To determine the effectiveness of the monoclonal antibody dinutuximab, in terms of adverse effects, survival rates and responses, in pediatric patients with high-risk neuroblastoma.<br/>Materials and Methods:<br/>A literature review of scientific articles was conducted using various electronic databases, including Pubmed, Cochrane, and Scopus.<br/>Results:<br/>A total of 8 articles meeting the inclusion criteria were identified, focusing on the effectiveness of neuroblastoma treatment in high-risk patients using monoclonal antibodies. The use of the monoclonal antibody dinutuximab was analyzed in terms of survival rates, as well as adverse effects compared to treatment without dinutuximab.<br/>Conclusions:<br/>In summary, treatment with dinutuximab in patients with high-risk neuroblastoma resulted in increased survival rates and a higher number of treatment responses.<br/>Additionally, analyses of adverse effects associated with infusions of this treatment were conducted. |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
neuroblastoma |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
terapia |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
alto riesgo |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
inmunoterapia |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
quimioinmunoterapia |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
terapia de mantenimiento |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
neuroblastoma |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
therapy |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
high risk |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
immunotherapy |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
chemoimmunotherapy |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
maintenance therapy |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Jiménez, Elena |
| 9 (RLIN) |
4404 |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
Universidad Pontificia de Salamanca. |
| Subordinate unit |
Facultad de Enfermería y Fisioterapia Salus Infirmorum. |
| -- |
Grado en Enfermería. |
| 9 (RLIN) |
489 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Universal Decimal Classification |
| Koha item type |
TFG/TFM |
